Carole Nuechterlein - Feb 27, 2024 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Director
Signature
/s/ Lesley Ann Calhoun, as attorney-in fact for Carole Nuechterlein
Stock symbol
ALGS
Transactions as of
Feb 27, 2024
Transactions value $
$0
Form type
4
Date filed
2/28/2024, 05:29 PM
Previous filing
Oct 27, 2023
Next filing
Jun 28, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Disposed to Issuer $0 -15K -100% $0.00* 0 Feb 27, 2024 Common Stock 15K $26.58 Direct F1
transaction ALGS Stock Option (Right to Buy) Award $0 +4.41K $0.00 4.41K Feb 28, 2024 Common Stock 4.41K $0.96 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share.
F2 The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.